5 years ago

Valo Therapeutics Secures EUR 1.1M for Clinical Trials

  • Valo Therapeutics, an immuno-oncology company developing tumour antigen-coated oncolytic viruses as therapeutic vaccines, has raised an additional EUR1.1m in funding

  • The funding will be used to progress its PeptiCRAd platform into first-in-human clinical trials

  • The company has now raised a total of over EUR 10m.

      • ProblemHealthcare

      "Existing cancer treatments often have significant side effects and are not always effective. Valo Therapeutics is trying to solve the problem of limited treatment options and poor outcomes for patients with cancer."

      Solution

      "Valo Therapeutics is developing a new type of cancer treatment that uses oncolytic viruses coated with tumour antigens to target and destroy cancer cells. This approach aims to provide a more effective and less toxic treatment option for patients with cancer."

      Covered on